An Investigational Immuno-therapy Study of Experimental Medication BMS-986178 by Itself or in Combination With Nivolumab and/or Ipilimumab in Patients With Solid Cancers That Are Advanced or Have Spread - CA012-004
Updated: 23 July, 2018 | ClinicalTrials.gov
The following study arms are currently recruiting:
See below for more information on study arms.
For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com Inclusion Criteria: - Patients must have at least 1 standard treatment regimen in the advanced, recurrent or metastatic setting - ECOG (Eastern Cooperative Oncology Group) 0-1 - Men and women 18 years old or older - At least one measurable lesion at baseline by CT (computed tomography) or MRI (magnetic resonance imaging) as per RECIST (Response Evaluation Criteria In Solid Tumors) v1.1 - All subjects must have a fresh tumor biopsy Exclusion Criteria: - Known central nervous system metastases or central nervous system as the only source of disease - Concomitant malignancies - Active known or suspected autoimmune disease - Uncontrolled or significant cardiovascular disease - Major surgery less than 4 weeks before the start of the study - Patients with known allergies to egg products, neomycin, or tetanus toxoid - Prior adverse reaction to tetanus toxoid-containing vaccines Other protocol defined inclusion/exclusion criteria could apply